Evidence map›Paper›PMID 41050430›Full record

ArticleMolecular therapy. Oncology2025

HIF1A, BRG1, and p300 interaction confers paclitaxel-induced drug resistance by enabling the overexpression of

Karolina Gronkowska, Kinga Kołacz-Milewska, Sylwia Michlewska, Tomasz Płoszaj, Maciej Borowiec, Agnieszka Robaszkiewicz

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Progress and challenges in the development of advanced pancreatic cancer organoids.Journal of experimental & clinical cancer research : CR · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Karolina GronkowskaDepartment of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236 Lodz, Poland.
Kinga Kołacz-MilewskaDepartment of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236 Lodz, Poland.
Sylwia MichlewskaLaboratory of Microscopic Imaging and Specialized Biological Techniques, Faculty of Biology and Environmental Protection, University of Lodz, Banacha 12/16, 90-237 Lodz, Poland.
Tomasz PłoszajDepartment of Clinical Genetics, Medical University of Lodz, Pomorska 251, 92-213 Lodz, Poland.
Maciej BorowiecDepartment of Clinical Genetics, Medical University of Lodz, Pomorska 251, 92-213 Lodz, Poland.
Agnieszka RobaszkiewiczDepartment of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236 Lodz, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of resistance to paclitaxel (PTX), which is a vital anticancer drug treating breast and lung cancers, can cause treatment failure and limit further use of taxanes and similar drugs. As previously documented, PTX-induced irresponsiveness to chemotherapy involves the overexpression of ABCC3, ABCC5, and ABCC10 members of the ATP-binding cassette (ABC) transmembrane proteins, which are enriched in the lysosomes of drug-resistant cells where anticancer drugs are actively trapped. In this paper, the role of HIF1A in a BRG1-p300-dependent overexpression of 3

Indexed as

ATP-binding cassette transportersBRG1chemotherapy responseEP300HIF1alysosomal trappingMT: Regular Issuemultidrug resistancepaclitaxeltranscription co-activation

Identifiers

PMID41050430
PMCPMC12493206

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.